Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
Date:5/8/2013

arter was $16.5 million, or $0.12 per share, compared with a net loss of $17.0 million, or $0.13 per share, for the same period in fiscal 2012.

Fiscal 2013 Six-Month Results

  • Total net revenues for the first six-months of fiscal 2013 totaled $34.0 million, compared with $17.2 million for the first six months of fiscal 2012.
  • Total operating expenses, excluding cost of sales and share-based compensation were $55.4 million in the first six-months of fiscal 2013, compared to $47.0 million in the comparable period for fiscal 2012.
  • Cash used in operations was $22.3 million in the first six months of fiscal 2013.
  • Net loss for the first six-months of fiscal 2013 was $28.6 million, or $0.21 per share, compared with a net loss of $33.0 million, or $0.25 per share for the comparable period in fiscal 2012.
  • NUEDEXTA Revenue
    For the quarter ended March 31, 2013, the company reported NUEDEXTA gross and net revenue of $20.8 million and $16.5 million respectively. Second quarter fiscal 2013 NUEDEXTA net revenue increased 81% versus the previous year and 11% over the previous quarter.

    Cash, Cash Equivalents & Marketable Securities
    As of March 31, 2013 Avanir had cash, cash equivalents and restricted investments totaling $70.2 million, including cash and cash equivalents of $67.9 million.

    Business Highlights

  • The company reported an eighth consecutive quarter of NUEDEXTA unit growth in both business channels with 13% retail and 4% institutional growth.
  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NUEDEXTA, recommending it be approved in two dosage strengths for the treatment of pseudobulbar affect (PBA), irrespective of neurologic cause.
  • The company appointed Corinne Nevinny, a seasoned life sciences executive with broad healthcare industry experience, to the company's board of directors.
  • N
    '/>"/>

    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    3. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    4. AVANIR Pharmaceuticals To paticipate in two conferences in March
    5. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    6. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    7. Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call
    8. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
    9. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
    (Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
    (Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
    Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
    ... J. Fox Foundation for Parkinson,s Research awarded about $2.9 ... drugs already approved in other disease indications for potential ... are already known to be safe for humans, they ... use in Parkinson,s patients if they prove effective in ...
    ... 12 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human viral ... initiated a proof-of-concept study of IDX184, a liver-targeted nucleotide ... Investigational New Drug application (IND) with the U.S. Food ...
    Cached Medicine Technology:Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4
    (Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
    (Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
    (Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
    (Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
    (Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
    Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
    ... birth weight or were not breast-fed may be// at a ... the University at Buffalo who presented this finding at the ... is especially true for women in their pre-menopausal age. ... is the most important phase of life for the development ...
    ... omega-3 fatty acids in their diet during pregnancy and ... daughter’s risk of breast cancer., ,Scientists from Louisiana ... 96th Annual Meeting of the American Association for Cancer ... have diet rich in omega 3 fatty acids will ...
    ... study by the computational neuroscientist of Vanderbilt University have ... insight into neural circuits that play a role in ... make us apply previously learned rules on new situations ... that the new use of technology in understanding developmental ...
    ... that extracts of the grapefruit seeds contain antioxidants ... a fruit, grapefruit had been associated with acidity ... and helpful ingredients that have healing properties. Researchers ... and presented their study findings at the Digestive ...
    ... Regular use of aspirin among patients of colon cancer after ... or death. ,In a study which was presented at ... that the risk of recurrence reduces by about 50% for ... were diagnosed as suffering from colon cancer. ,Colon and ...
    ... that for people whose blood pressure do not lower //during ... ,In a healthy normal person blood pressure tends to lower ... sleep disturbances may elevate the nighttime blood pressures. ... levels of blood pressure at night may be the predictor ...
    Cached Medicine News:
    ... High Speed Performance of Daily Routine ... Requirements and Information. VISUPAC has been ... Important for routine operation is the ... sequences. Extensive default settings reduce the ...
    ... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
    ... use with patients who have cataract and ... is a semicircular elastic PMMA ring for ... It is supplied in sterile packing for ... pupil during phacoemulsification for patients who have ...
    To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
    Medicine Products: